Search
Search Results
##search.searchResults.foundPlural##
-
STUDY OF SERUM HAPTOGLOBIN LEVEL AND ITS RELATION TO ERYTHROPOIETIC ACTIVITY IN BETA THALASSEMIA CHILDREN .
2133PDF: 1144HTML: 2575Study of serum haptoglobin level in thalassemia: 323Figures: 162 -
-
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1334PDF: 1275HTML: 81 -
FASTING PLASMA GLUCOSE LEVELS WITHIN THE HIGH NORMAL RANGE ARE ASSOCIATED WITH A SIGNIFICANTLY INCREASED RISK OF FUTURE DYSGLYCEMIA IN TRANSFUSION-DEPENDENT Β THALASSEMIA: A DECADE-LONG MULTICENTER RETROSPECTIVE ANALYSIS Higher normal fasting plasma glucose and glucose dysregulation in β- thalassemia
563PDF: 203Html: 25 -
COULD PLASMA GLUCOSE (PG) INCREMENT (PG %) EXPAND THE CLINICAL WEIGHT OF OGTT? PRELIMINARY FINDINGS IN 19 TDT PATIENTS (Β-TDT) WITH NORMAL GLUCOSE TOLERANCE Plasma glucose (PG) increment (PG %) and pancretic β-cell dysfunction in thalassemia
647PDF: 474HTML: 31 -
Cardiac toxicity associated with HCV direct antiviral agents Heart in HCV DAAs therapy
1519PDF: 951HTML: 165 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2010PDF: 1616HTML: 347 -
THE ROLE OF THE CAROTID DOPPLER EXAMINATION IN THE EVALUATION OF ATHEROSCLEROTIC CHANGES IN BETA THALASSEMIA PATIENTS
2111PDF: 887HTML: 2992Untitled: 193 -
MEDICAL TREATMENT OF HEPATOCELLULAR CARCINOMA
710PDF: 455HTML: 6249 -
TUBERCULOSIS IN HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS.
2577PDF: 916HTML: 3585 -
THE IMPACT OF HUMAN PLATELET ANTIGEN ALLELE ON ANTIPLATELET ANTIBODIES AND CRYOGLOBULINS IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA AND HEPATITIS C VIRUS-ASSOCIATED IMMUNE THROMBOCYTOPENIA Human platelet antigen and immune thrombocytopenia
967PDF: 825Suppl. Files: 440HTML: 273 -
PERSISTENT COLONIC SCHISTOSOMIASIS AMONG SYMPTOMATIC RURAL INHABITANTS IN THE EGYPTIAN NILE DELTA Colonic schistosomiasis among rurals of the Egyptian Nile delta
1418PDF: 452MP4: 389Html: 180 -
CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
4731PDF: 1725HTML: 2690Untitled: 197 -
IMMUNOLOGY OF TUBERCULOSIS
5161PDF: 1969HTML: 7254Untitled: 188 -
Severe autoimmune hemolytic anemia in Covid-19 infection Autoimmune hemolytic anemia in Covid-19
3091PDF: 1549HTML: 251 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
1892PDF: 720HTML: 681 -
The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones
1183PDF: 739HTML: 299 -
The COVID-19 in Omani children with chronic Hemato-oncology diseases COVID-19 in Omani children with chronic Hemato-oncology diseases
780PDF: 667HTML: 294 -
THE GUT MICROBIOTA AND IMMUNE SYSTEM RELATIONSHIP IN HUMAN GRAFT-VERSUS-HOST DISEASE
6206PDF: 2057HTML: 13979Untitled: 185figure: 167 -
HIV INFECTION, ANTIRETROVIRAL THERAPY AND CARDIOVASCULAR RISK
1776PDF: 780HTML: 3584 -
IRON DEFICIENCY ANAEMIA AMONG PRE-SCHOOL CHILDREN WITH SICKLE CELL ANAEMIA: STILL A RARE DIAGNOSIS?
1279PDF: 804HTML: 2885cover leer: 135 -
THERAPY-RELATED MYELOID NEOPLASMS: CONSIDERATIONS FOR PATIENTS’ CLINICAL EVALUATION. Clinical Evaluation of T-AML
1553PDF: 780HTML: 144 -
ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
2778PDF: 1199HTML: 2676Figure 1: 155 -
-
The EVOLVING ROLE OF HAEMATOLOGY NURSING PRACTICE: A CROSS-SECTIONAL SURVEY
1693Suppl. Files: 837HTML: 407PDF: 711 -
PEDIATRIC MASTOCYTOSIS: AN UPDATE Chldren' Mastocytosis
1781HTML: 1384PDF: 1040 -
Follicular Lymphoma: A Clinicopathological Analysis from a Tertiary care Institute in Southern India
3138PDF: 753HTML: 2920Figure 1a and 1b: 137Figure 2: 143Figure 3: 165Figure 4: 144Figure 5: 149Tables 1-5: 142 -
COAGULOPATHY IN BETA-THALASSEMIA: CURRENT UNDERSTANDING AND FUTURE PERSPECTIVES
1046PDF: 472HTML: 8139 -
JUSTIFICATION OF UNIVERSAL IRON SUPPLEMENTATION FOR INFANTS 6-12 MONTHS IN REGIONS WITH A HIGH PREVALENCE OF THALASSEMIA Iron Supplementation for Infants 6-12 months in Regions with a High Prevalence of Thalassemia
1992PDF: 585Suppl. Files: 272HTML: 153







